Market Cap : 842 M | Enterprise Value : 820.2 M | PE Ratio : 23.05 | PB Ratio : 10.33 |
---|
NAS:NRC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:NRC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2022-05-16), National Research's Intrinsic Value: Projected FCF is $16.58. The stock price of National Research is $33.42. Therefore, National Research's Price-to-Intrinsic-Value-Projected-FCF of today is 2.0.
The historical rank and industry rank for National Research's Intrinsic Value: Projected FCF or its related term are showing as below:
During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of National Research was 5.72. The lowest was 1.28. And the median was 2.61.
The historical data trend for National Research's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, National Research's Intrinsic Value: Projected FCF, along with its competitors' market caps and Intrinsic Value: Projected FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Healthcare Providers & Services industry and Healthcare sector, National Research's Intrinsic Value: Projected FCF distribution charts can be found below:
* The bar in red indicates where National Research's Intrinsic Value: Projected FCF falls into.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)
In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):
Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)
Add all the Free Cash Flow together and divide 6 will get National Research's Free Cash Flow(6 year avg) = $31.92.
National Research's Intrinsic Value: Projected FCF for today is calculated as
Intrinsic Value: Projected FCF | = | (Growth Multiple | * | Free Cash Flow (6 year avg) | + | Total Stockholders Equity (Mar22) | * | 0.8) | / | Shares Outstanding (Diluted Average) |
= | (11.145567245439 | * | 31.92176 | + | 81.486 | * | 0.8) | / | 25.390 | |
= | 16.58 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
National Research's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF | = | Share Price | / | Intrinsic Value: Projected FCF |
= | 33.42 | / | 16.580343547569 | |
= | 2.02 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of National Research's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Jackson Steven D. | officer: President | C/O NATIONAL RESEARCH CORPORATION 1245 Q STREET LINCOLN NE 68508 |
Martin Joann M | director | 6221 ANDREW COURT LINCOLN NE 68512 |
Nunnelly John N | director | P.O. BOX 2175 AMHERST MA 01004 |
Karas Kevin R | officer: SVP Finance, CFO, Treas & Secy | C/O NATIONAL RESEARCH CORPORATION 1245 Q STREET LINCOLN NE 68508 |
Berwick Donald M | director | C/O NATIONAL RESEARCH CORPORATION 1245 Q STREET LINCOLN NE 68508 |
Mowry Barbara | director | P.O. BOX 103115 DENVER CO 80250 |
Amandla Mk Trust | 10 percent owner | C/O THE BRYN MAWR TRUST COMPANY OF DELAW 20 MONTCHANIN RD, SUITE 100 GREENVILLE DE 19807 |
Hays Michael D. | director, officer: CEO | C/O NATIONAL RESEARCH CORPORATION 1245 Q STREET LINCOLN NE 68508 |
K/i/e Trust Under Agreement 10/24/18 | 10 percent owner | C/O BESSEMER TRUST COMPANY OF DELAWARE 1007 N. ORANGE ST., SUITE 1450 WILMINGTON DE 19801 |
Endacott Kent E. | 10 percent owner | C/O WOODS & AITKEN LLP 301 SOUTH 13TH STREET, SUITE 500 LINCOLN NE 68508 |
Beans Patrick E | director, officer: CFO and Secretary | AMANDLA LLC 709 PIER 2 LINCOLN NE 68528 |
Warden Gail L | director | 250 WASHINGTON RD GROSSE POINTE MI 48230 |
Henricks Susan L | officer: President and COO | C/O NATIONAL RESEARCH CORPORATION 1245 Q STREET LINCOLN NE 68508 |
Schorr Paul C Iii | director | PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: SCHORR PAUL C III a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;} |
Peetz Jeffery T | 10 percent owner | WOODS & AITKEN LLP 301 SOUTH 13TH STREET, SUITE 500 LINCOLN NE 68508 |
Other Sources
By Seekingalpha 2022-02-09